Arbutus Biopharma Corp — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that Arbutus Biopharma Corp filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $14.08M | Mar 23, 2026 |
| FY2025 | Dec 31, 2024 | $6.17M | Mar 23, 2026 |
| FY2024 | Dec 31, 2023 | $18.14M | Mar 27, 2025 |
| FY2023 | Dec 31, 2022 | $39.02M | Mar 5, 2024 |
| FY2022 | Dec 31, 2021 | $10.99M | Mar 2, 2023 |
| FY2021 | Dec 31, 2020 | $6.91M | Mar 3, 2022 |
| FY2019 | Dec 31, 2019 | $1.62M | Mar 5, 2020 |
| FY2019 | Sep 30, 2019 | $3.06M | Mar 5, 2020 |
| FY2019 | Jun 30, 2019 | $653.0K | Mar 5, 2020 |
| FY2019 | Mar 31, 2019 | $679.0K | Mar 5, 2020 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($33.50M) | Mar 23, 2026 |
| FY2025 | Dec 31, 2024 | ($69.92M) | Mar 23, 2026 |
| FY2024 | Dec 31, 2023 | ($72.85M) | Mar 27, 2025 |
| FY2023 | Dec 31, 2022 | ($69.46M) | Mar 5, 2024 |
| FY2022 | Dec 31, 2021 | ($76.25M) | Mar 2, 2023 |
| FY2021 | Dec 31, 2020 | ($63.75M) | Mar 3, 2022 |
| FY2019 | Dec 31, 2019 | ($24.65M) | Mar 5, 2020 |
| FY2019 | Sep 30, 2019 | ($82.50M) | Mar 5, 2020 |
| FY2019 | Jun 30, 2019 | ($23.32M) | Mar 5, 2020 |
| FY2019 | Mar 31, 2019 | ($23.25M) | Mar 5, 2020 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($38.16M) | Mar 23, 2026 |
| FY2025 | Dec 31, 2024 | ($76.32M) | Mar 23, 2026 |
| FY2024 | Dec 31, 2023 | ($78.10M) | Mar 27, 2025 |
| FY2023 | Dec 31, 2022 | ($65.46M) | Mar 5, 2024 |
| FY2022 | Dec 31, 2021 | ($73.52M) | Mar 2, 2023 |
| FY2021 | Dec 31, 2020 | ($57.81M) | Mar 3, 2022 |
| FY2019 | Dec 31, 2019 | ($13.09M) | Mar 5, 2020 |
| FY2019 | Sep 30, 2019 | ($91.40M) | Mar 5, 2020 |
| FY2019 | Jun 30, 2019 | ($20.52M) | Mar 5, 2020 |
| FY2019 | Mar 31, 2019 | ($19.07M) | Mar 5, 2020 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $25.24M | Mar 23, 2026 |
| FY2025 | Dec 31, 2024 | $54.04M | Mar 23, 2026 |
| FY2024 | Dec 31, 2023 | $73.70M | Mar 27, 2025 |
| FY2023 | Dec 31, 2022 | $84.41M | Mar 5, 2024 |
| FY2022 | Dec 31, 2021 | $65.50M | Mar 2, 2023 |
| FY2021 | Dec 31, 2020 | $49.34M | Mar 3, 2022 |
| FY2020 | Dec 31, 2019 | $57.60M | Mar 4, 2021 |
| FY2019 | Dec 31, 2018 | $57.93M | Mar 5, 2020 |
| FY2018 | Dec 31, 2017 | $62.68M | Mar 7, 2019 |
| FY2017 | Dec 31, 2016 | $61.25M | Mar 16, 2018 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($39.64M) | Mar 23, 2026 |
| FY2025 | Dec 31, 2024 | ($64.85M) | Mar 23, 2026 |
| FY2024 | Dec 31, 2023 | ($85.94M) | Mar 27, 2025 |
| FY2023 | Dec 31, 2022 | ($35.36M) | Mar 5, 2024 |
| FY2022 | Dec 31, 2021 | ($67.53M) | Mar 2, 2023 |
| FY2021 | Dec 31, 2020 | ($51.44M) | Mar 3, 2022 |
| FY2020 | Dec 31, 2019 | ($71.01M) | Mar 4, 2021 |
| FY2019 | Dec 31, 2018 | ($67.87M) | Mar 5, 2020 |
| FY2018 | Dec 31, 2017 | ($48.64M) | Mar 7, 2019 |
| FY2017 | Dec 31, 2016 | ($57.89M) | Mar 16, 2018 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $0 | Mar 23, 2026 |
| FY2025 | Dec 31, 2024 | $182.0K | Mar 23, 2026 |
| FY2024 | Dec 31, 2023 | $1.01M | Mar 27, 2025 |
| FY2023 | Dec 31, 2022 | $512.0K | Mar 5, 2024 |
| FY2022 | Dec 31, 2021 | $809.0K | Mar 2, 2023 |
| FY2021 | Dec 31, 2020 | $229.0K | Mar 3, 2022 |
| FY2020 | Dec 31, 2019 | $589.0K | Mar 4, 2021 |
| FY2019 | Dec 31, 2018 | $1.14M | Mar 5, 2020 |
| FY2018 | Dec 31, 2017 | $7.26M | Mar 7, 2019 |
| FY2017 | Dec 31, 2016 | $4.00M | Mar 16, 2018 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $94.62M | Mar 23, 2026 |
| FY2025 | Dec 31, 2024 | $131.71M | Mar 23, 2026 |
| FY2024 | Dec 31, 2023 | $144.40M | Mar 27, 2025 |
| FY2023 | Dec 31, 2022 | $195.42M | Mar 5, 2024 |
| FY2022 | Dec 31, 2021 | $204.49M | Mar 2, 2023 |
| FY2021 | Dec 31, 2020 | $137.08M | Mar 3, 2022 |
| FY2020 | Dec 31, 2019 | $105.54M | Mar 4, 2021 |
| FY2019 | Dec 31, 2018 | $227.91M | Mar 5, 2020 |
| FY2018 | Dec 31, 2017 | $237.16M | Mar 7, 2019 |
| FY2017 | Dec 31, 2016 | $275.92M | Mar 16, 2018 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $18.04M | Mar 23, 2026 |
| FY2025 | Dec 31, 2024 | $34.34M | Mar 23, 2026 |
| FY2024 | Dec 31, 2023 | $38.38M | Mar 27, 2025 |
| FY2023 | Dec 31, 2022 | $58.57M | Mar 5, 2024 |
| FY2022 | Dec 31, 2021 | $35.05M | Mar 2, 2023 |
| FY2021 | Dec 31, 2020 | $35.11M | Mar 3, 2022 |
| FY2020 | Dec 31, 2019 | $32.79M | Mar 4, 2021 |
| FY2019 | Dec 31, 2018 | $27.67M | Mar 5, 2020 |
| FY2018 | Dec 31, 2017 | $54.69M | Mar 7, 2019 |
| FY2017 | Dec 31, 2016 | $72.91M | Mar 16, 2018 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $76.58M | Mar 23, 2026 |
| FY2025 | Dec 31, 2024 | $97.37M | Mar 23, 2026 |
| FY2025 | Dec 31, 2023 | $106.02M | Mar 23, 2026 |
| FY2024 | Dec 31, 2022 | $136.85M | Mar 27, 2025 |
| FY2023 | Dec 31, 2021 | $169.44M | Mar 5, 2024 |
| FY2022 | Dec 31, 2020 | $101.97M | Mar 2, 2023 |
| FY2021 | Dec 31, 2019 | $72.74M | Mar 3, 2022 |
| FY2020 | Dec 31, 2018 | $200.23M | Mar 4, 2021 |
| FY2019 | Dec 31, 2017 | $182.47M | Mar 5, 2020 |
| FY2018 | Dec 31, 2016 | $203.01M | Mar 7, 2019 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2020 | Dec 31, 2019 | $0 | Mar 4, 2021 |
| FY2019 | Dec 31, 2018 | $22.47M | Mar 5, 2020 |
| FY2018 | Dec 31, 2017 | $24.36M | Mar 7, 2019 |
| FY2017 | Dec 31, 2016 | $24.36M | Mar 16, 2018 |
| FY2016 | Dec 31, 2015 | $162.51M | Mar 22, 2017 |
| FY2015 | Dec 31, 2014 | $0 | Mar 9, 2016 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($1.38B) | Mar 23, 2026 |
| FY2025 | Dec 31, 2024 | ($1.35B) | Mar 23, 2026 |
| FY2024 | Dec 31, 2023 | ($1.28B) | Mar 27, 2025 |
| FY2023 | Dec 31, 2022 | ($1.20B) | Mar 5, 2024 |
| FY2022 | Dec 31, 2021 | ($1.13B) | Mar 2, 2023 |
| FY2021 | Dec 31, 2020 | ($1.05B) | Mar 3, 2022 |
| FY2020 | Dec 31, 2019 | ($970.09M) | Mar 4, 2021 |
| FY2019 | Dec 31, 2018 | ($805.22M) | Mar 5, 2020 |
| FY2018 | Dec 31, 2017 | ($738.07M) | Mar 7, 2019 |
| FY2017 | Dec 31, 2016 | ($652.75M) | Mar 16, 2018 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $18.01M | Mar 23, 2026 |
| FY2025 | Dec 31, 2024 | $36.33M | Mar 23, 2026 |
| FY2024 | Dec 31, 2023 | $26.29M | Mar 27, 2025 |
| FY2023 | Dec 31, 2022 | $30.78M | Mar 5, 2024 |
| FY2022 | Dec 31, 2021 | $109.28M | Mar 2, 2023 |
| FY2021 | Dec 31, 2020 | $52.25M | Mar 3, 2022 |
| FY2020 | Dec 31, 2019 | $31.80M | Mar 4, 2021 |
| FY2019 | Dec 31, 2018 | $36.94M | Mar 5, 2020 |
| FY2019 | Dec 31, 2017 | $54.29M | Mar 5, 2020 |
| FY2018 | Dec 31, 2016 | $23.41M | Mar 7, 2019 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $0 | Mar 23, 2026 |
| FY2024 | Dec 31, 2024 | $0 | Mar 27, 2025 |
| FY2023 | Dec 31, 2023 | $0 | Mar 5, 2024 |
| FY2022 | Dec 31, 2022 | $0 | Mar 2, 2023 |
| FY2021 | Dec 31, 2021 | $0 | Mar 3, 2022 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Mar 23, 2026 |
| FY2025 | Dec 31, 2024 | 0 | Mar 23, 2026 |
| FY2024 | Dec 31, 2023 | 0 | Mar 27, 2025 |
| FY2023 | Dec 31, 2022 | 0 | Mar 5, 2024 |
| FY2022 | Dec 31, 2021 | 0 | Mar 2, 2023 |
| FY2021 | Dec 31, 2020 | (1) | Mar 3, 2022 |
| FY2019 | Dec 31, 2019 | 0 | Mar 5, 2020 |
| FY2019 | Sep 30, 2019 | (1) | Mar 5, 2020 |
| FY2019 | Jun 30, 2019 | 0 | Mar 5, 2020 |
| FY2019 | Mar 31, 2019 | 0 | Mar 5, 2020 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Mar 23, 2026 |
| FY2025 | Dec 31, 2024 | 0 | Mar 23, 2026 |
| FY2024 | Dec 31, 2023 | 0 | Mar 27, 2025 |
| FY2023 | Dec 31, 2022 | 0 | Mar 5, 2024 |
| FY2022 | Dec 31, 2021 | 0 | Mar 2, 2023 |
| FY2021 | Dec 31, 2020 | (1) | Mar 3, 2022 |
| FY2018 | Dec 31, 2018 | 0 | Mar 7, 2019 |
| FY2018 | Sep 30, 2018 | 0 | Mar 7, 2019 |
| FY2018 | Jun 30, 2018 | 0 | Mar 7, 2019 |
| FY2018 | Mar 31, 2018 | 0 | Mar 7, 2019 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 192.53M | Mar 23, 2026 |
| FY2025 | Dec 31, 2024 | 189.96M | Mar 23, 2026 |
| FY2024 | Dec 31, 2023 | 169.87M | Mar 27, 2025 |
| FY2023 | Dec 31, 2022 | 157.46M | Mar 5, 2024 |
| FY2022 | Dec 31, 2021 | 144.99M | Mar 2, 2023 |
| FY2021 | Dec 31, 2020 | 89.68M | Mar 3, 2022 |
| FY2020 | Dec 31, 2019 | 64.78M | Mar 4, 2021 |
| FY2019 | Dec 31, 2018 | 55.52M | Mar 5, 2020 |
| FY2018 | Dec 31, 2017 | 55.06M | Mar 7, 2019 |
| FY2017 | Dec 31, 2016 | 54.84M | Mar 16, 2018 |